达考替丁 | 120958-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 达考替丁
• 英文名称: N-Ethyl-N'-[3-(3-piperidinomethylphenoxy)propyl]urea
• 英文别名: dalcotidine；1-ethyl-3-[3-[3-(piperidin-1-ylmethyl)phenoxy]propyl]urea
• CAS: 120958-90-9
• 化学式: C₁₈H₂₉N₃O₂
• 分子量: 319.447
• InChiKey: SVCQBXMFONNZHX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  53.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-3-[3-(1-哌啶甲基)-苯氧基]丙胺 以89的产率得到达考替丁
  参考文献：
  名称：

  J. Med. Chem. 1992, 35, 2446-2451

  摘要：

  DOI：

文献信息

• Anti-ulcer urea derivatives
  申请人：Kyorin Pharmaceutical Co., Ltd.

  公开号：US04952591A1

  公开（公告）日：1990-08-28

  Urea derivatives of the following formula, ##STR1## wherein R.sub.1 indicates a piperidino group or pyrrolidino group which may be substituted with hydroxy group or lower alkyl group having 1 to 3 carbon atoms; A indicates an ethylene group, propylene group, butylene group or butenylene group; R.sub.2 indicates a straight or branched alkyl group having 1 to 20 carbon atoms, cycloalkyl group having 3 to 6 carbon atoms, benzyl group, or phenyl group which may have 1 to 3 substituents such as lower alkyl group having 1 to 6 carbon atoms, lower alkoxy group having 1 to 3 carbon atoms, halogen atom, trifluoromethyl group, amino group, nitro group or methylenedioxy group; X indicates an oxygen or sulfur atom, the hydrates and pharmaceutically acceptable acid addition salts thereof are useful as antiulcer agents.

  尿素衍生物的化学式如下：##STR1## 其中R.sub.1表示一个哌啶基团或吡咯啉基团，可以被氢氧基或含有1至3个碳原子的较低烷基基团取代；A表示一个乙烯基、丙烯基、丁烯基或丁二烯基；R.sub.2表示一个直链或支链烷基基团，含有1至20个碳原子，环烷基基团，含有3至6个碳原子，苄基或苯基，可能有1至3个取代基，如含有1至6个碳原子的较低烷基基团、含有1至3个碳原子的较低烷氧基团、卤原子、三氟甲基基团、氨基、硝基或亚甲基二氧基基团；X表示一个氧原子或硫原子，其水合物和药学上可接受的酸盐对抗溃疡剂具有用途。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
  申请人：Scaramuzzino, Giovanni

  公开号：EP1336602A1

  公开（公告）日：2003-08-20

  New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

  通式（I）的新药物化合物：F-（X）q，其中q是1到5的整数，最好是1；-F是在文本中描述的药物中选择的，-X是在文本中描述的4个组-M，-T，-V和-Y中选择的。通式（I）的化合物是硝酸盐前药，可以在体内以受控和选择性的方式释放一氧化氮，而不会产生降压副作用，因此它们非常适用于制备用于预防和治疗肌肉骨骼，皮肤，呼吸，消化，泌尿和中枢神经系统的炎症，缺血，退行性和增生性疾病的药物。
• Carboxylic acid derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0454449A1

  公开（公告）日：1991-10-30

  The invention relates to salts formed between basic H2-receptor antagonists and a complex of zinc with a carboxylic acid selected from tartaric acid, citric acid and alkyl citric acids, and to solvates of such salts, excluding salts in which the basic H2-receptor antagonist is ranitidine. Examples of basic H2-receptor antagonists are cimetidine, famotidine, nizatidine and roxatidine. The salts are useful in the treatment of gastrointestinal disorders, such as peptic ulcer disease and non-ulcer dyspepsia.

  本发明涉及碱性 H2 受体拮抗剂和锌与选自酒石酸、柠檬酸和烷基柠檬酸的羧酸的络合物之间形成的盐，以及此类盐的溶液，不包括碱性 H2 受体拮抗剂为雷尼替丁的盐。碱性 H2 受体拮抗剂的例子有西咪替丁、法莫替丁、尼扎替丁和罗沙替丁。 这些盐类可用于治疗胃肠道疾病，如消化性溃疡病和非溃疡性消化不良。
• Pharmaceutical combinations of rivaroxaban and H2-receptor antagonists
  申请人：Sanovel Ilac Sanayi ve Ticaret A.S.

  公开号：EP2942058A1

  公开（公告）日：2015-11-11

  This invention is a novel pharmaceutical composition comprising rivaroxaban or a pharmaceutically acceptable salt thereof in combination with a H2-receptor antagonist for use in the anticoagulant treatment with preventing or reducing the risk of a gastrointestinal disorder.

  本发明是一种新型药物组合物，由利伐沙班或其药学上可接受的盐与 H2 受体拮抗剂组合而成，用于抗凝治疗，预防或降低胃肠道疾病的风险。